The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL. Participants will be randomly assigned to two groups: the intervention group and the control group. They will receive: * Intervention group: Standard clinical treatment + BL capsules (10\^10 CFU), twice a day, for a total of 14 days; * Control group: Standard clinical treatment + placebo capsules, for a total of 14 days. A total of 60 patients will be included in this study.
Rationale:The impairment of the intestinal mucosal barrier in patients with acute pancreatitis (AP) plays a crucial role in the progression to severe AP(SAP). Our previous research found that the early gut microbiota structure of AP patients is significantly different from that of healthy individuals, characterized by a marked increase in the relative abundance of conditional pathogens such as Escherichia coli and Shigella, while beneficial bacteria that produce short-chain fatty acids, such as Bifidobacterium, are significantly reduced, especially in patients with SAP. Bifidobacterium longum (BL), a well-known probiotic, has been used to treat a variety of diseases. In our previous animal experiments, we found that BL could alleviate pancreatic damage and inflammatory responses in AP mice and regulate the balance of the gut microbiota. Based on these findings, this study aims to assess the impact of BL on the clinical prognosis of AP patients through a randomized controlled trial, in order to provide a scientific basis for the application of BL in the treatment of AP and to further explore its potential clinical value. Objective: The purpose of this clinical trial is to investigate the impact of BL on the clinical prognosis of patients with AP, to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL. Study design: Single-center, randomized, double-blind, placebo-controlled study. Study population:60 adult patients with acute pancreatitis. Intervention: The intervention group receives standard clinical treatment plus BL capsules (10\^10 CFU), twice a day, for a total of 14 days; the control group receives standard clinical treatment plus placebo capsules, for a total of 14 days. Main study parameters/endpoints: The primary endpoint is the number of days without SIRS within 14 days; the secondary endpoints include infectious complications (including fungal infections), parameters related to systemic inflammatory response, intestinal barrier function and gut microbiota composition, indicators related to recovery of intestinal function, antibiotic use, laboratory-related indicators, and clinical outcomes. Safety: Throughout the study (or afterwards), treatment-emergent adverse events (TEAEs) were recorded, including gastrointestinal adverse reactions (abdominal pain, nausea, vomiting, bloating, or diarrhea) and allergic reactions, and adverse events that led to discontinuation of the study drug were documented.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
Bifidobacterium longum
Placebo
Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The number of days without SIRS within 14 days
Patients were randomized into the study group and remained free of SIRS up to 14 days after enrollment, with the total number of SIRS-free days counted
Time frame: From randomization to 14 days after treatment
Infectious complications
The occurence of infected pancreatic necrosis, bacteremia, pneumonia, urosepsis, and/or infected ascites，including fungal infections
Time frame: During the whole study period including follow-up of 90 days
Intestinal barrier function
Plasma D-lactate(D-lac）
Time frame: Through study completion, an average of 1 year
Intestinal barrier function
Diamine oxidase activity(DAO)
Time frame: Through study completion, an average of 1 year
Intestinal barrier function
Plasma endotoxin levels
Time frame: Through study completion, an average of 1 year
Gut microbiota composition
Fecal samples were collected from patients prior to the start of treatment, as well as on days 3, 7, and 14 after treatment. Subsequently, DNA was extracted from the feces, and the DNA was fragmented by Covaris M220 to screen for fragments of approximately 350 bp to be constructed into paired-end (Paired-End) DNA libraries. Next, libraries were constructed using NEXTFLEX Rapid DNA-Seq. Finally, these libraries were subjected to macro-genomic sequencing for in-depth analysis of microbial community structure and function in the samples.
Time frame: Baseline , 3 days，7 days and 14 days of treatment
Systemic inflammatory response parameters (SIRS)
The incidence of persistent SIRS (lasting ≥48 hours)
Time frame: Through study completion, an average of 1 year
Systemic inflammatory response parameters (SIRS)
Trends in SIRS score changes
Time frame: Through study completion, an average of 1 year
Systemic inflammatory response parameters (SIRS)
Trends in CRP level changes
Time frame: Through study completion, an average of 1 year
Gut function recovery-related indicators
Improvement in abdominal signs
Time frame: Through study completion, an average of 1 year
Antibiotic usage
The number of days of antibiotic use
Time frame: Through study completion, an average of 1 year
Mortality
Occurence of death
Time frame: During the whole study period including follow-up of 90 days
(New onset) transient/persistant (multiple) organ failure
The occurence of (new onset) transient/persistant (multiple) organ failure
Time frame: During the whole study period including follow-up of 90 days
Disease severity according to the revised Atlanta Classification
Disease severity according to the revised Atlanta Classification
Time frame: During the whole study period including follow-up of 90 days
Length of hospital and/or ICU stay
Measured in days
Time frame: Through study completion, an average of 1 year
The need (and number of) for surgical, endoscopic or radiologic interventions
The need (and number of) for surgical, endoscopic or radiologic interventions
Time frame: During the whole study period including follow-up of 90 days
Readmissions
The occurrence and number of readmissions
Time frame: During the whole study period including follow-up of 90 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.